Search Results

There are 21087 results for: content related to: The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer

  1. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study

    BJU International

    Volume 106, Issue 7, October 2010, Pages: 974–978, Jean-Christophe Eymard, Stéphane Oudard, Gwenaelle Gravis, Jean-Marc Ferrero, Christine Theodore, Florence Joly, Frank Priou, Ivan Krakowski, Alain Zannetti, Laurence Thill and Philippe Beuzeboc

    Article first published online : 14 SEP 2010, DOI: 10.1111/j.1464-410X.2010.09296.x

  2. You have free access to this content
    Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer

    BJU International

    Volume 110, Issue 11b, December 2012, Pages: E635–E640, Matthias M. Heck, Mark Thalgott, Margitta Retz, Petra Wolf, Tobias Maurer, Roman Nawroth, Georgios Hatzichristodoulou, Jürgen E. Gschwend and Hubert Kübler

    Article first published online : 13 AUG 2012, DOI: 10.1111/j.1464-410X.2012.11364.x

  3. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel

    BJU International

    Philipp Nuhn, Ajay M. Vaghasia, Jatinder Goyal, Xian C. Zhou, Michael A. Carducci, Mario A. Eisenberger and Emmanuel S. Antonarakis

    Article first published online : 14 FEB 2014, DOI: 10.1111/bju.12531

  4. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer

    BJU International

    Guru Sonpavde, Gregory R. Pond, Andrew J. Armstrong, Matthew D. Galsky, Lance Leopold, Brian A. Wood, Shaw-Ling Wang, Jolanda Paolini, Isan Chen, Edna Chow-Maneval, David J. Mooney, Mariajose Lechuga, Matthew R. Smith and M. Dror Michaelson

    Article first published online : 17 JUL 2014, DOI: 10.1111/bju.12589

  5. You have free access to this content
    Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: The Australian perspective

    Asia-Pacific Journal of Clinical Oncology

    Volume 8, Issue 1, March 2012, Pages: 31–42, Phillip PARENTE, Francis PARNIS and Howard GURNEY

    Article first published online : 28 FEB 2012, DOI: 10.1111/j.1743-7563.2011.01506.x

  6. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer

    BJU International

    Volume 107, Issue s2, April 2011, Pages: 13–20, Sergio Bracarda, Christopher Logothetis, Cora N. Sternberg and Stéphane Oudard

    Article first published online : 7 MAR 2011, DOI: 10.1111/j.1464-410X.2010.10036.x

  7. Novel therapeutics for the management of castration-resistant prostate cancer (CRPC)

    BJU International

    Volume 109, Issue 7, April 2012, Pages: 968–985, Daniel J. Lee, Eugene K. Cha, Justin M. Dubin, Himisha Beltran, Thomas F. Chromecki, Harun Fajkovic, Douglas S. Scherr, Scott T. Tagawa and Shahrokh F. Shariat

    Article first published online : 28 OCT 2011, DOI: 10.1111/j.1464-410X.2011.10643.x

  8. You have free access to this content
    Castration-resistant prostate cancer: Many treatments, many options, many challenges ahead

    Cancer

    Volume 118, Issue 10, 15 May 2012, Pages: 2583–2593, Jorge A. Garcia and Brian I. Rini

    Article first published online : 28 OCT 2011, DOI: 10.1002/cncr.26582

  9. Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?

    BJU International

    Nicolas Mottet, Noel Clarke, Maria De Santis, Filiberto Zattoni, Juan Morote and Steven Joniau

    Article first published online : 15 JUL 2014, DOI: 10.1111/bju.12736

  10. You have free access to this content
    Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer

    Asia-Pacific Journal of Clinical Oncology

    Volume 10, Issue 3, September 2014, Pages: 205–215, Phillip Parente, Francis Parnis and Howard Gurney

    Article first published online : 3 APR 2014, DOI: 10.1111/ajco.12193

  11. You have free access to this content
    Dasatinib combined with docetaxel for castration-resistant prostate cancer

    Cancer

    Volume 118, Issue 1, 1 January 2012, Pages: 63–71, John C. Araujo, Paul Mathew, Andrew J. Armstrong, Edward L. Braud, Edwin Posadas, Mathew Lonberg, Gary E. Gallick, Géralyn C. Trudel, Prashni Paliwal, Shruti Agrawal and Christopher J. Logothetis

    Article first published online : 4 MAR 2011, DOI: 10.1002/cncr.26204

  12. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities

    BJU International

    Volume 110, Issue 5, September 2012, Pages: 658–667, Heather Payne, Amit Bahl, Malcolm Mason, Janis Troup and Johann De Bono

    Article first published online : 19 MAR 2012, DOI: 10.1111/j.1464-410X.2011.10886.x

  13. Docetaxel rechallenge in patients with metastatic castration-resistant prostate cancer

    BJU International

    Accepted manuscript online: 20 JUN 2014, S. Oudard, G. Kramer, O. Caffo, L. Creppy, Y. Loriot, S. Hansen, M. Holmberg, F. Rolland, J.P. Machiels and M. Krainer

    DOI: 10.1111/bju.12845

  14. New developments in castrate-resistant prostate cancer

    BJU International

    Volume 109, Issue s6, June 2012, Pages: 22–32, N. Shore, M. Mason and Th. M. de Reijke

    Article first published online : 4 JUN 2012, DOI: 10.1111/j.1464-410X.2012.11217.x

  15. Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer

    BJU International

    Volume 110, Issue s1, October 2012, Pages: 14–22, Noel W. Clarke

    Article first published online : 10 OCT 2012, DOI: 10.1111/j.1464-410X.2012.11430.x

  16. Cytotoxic chemotherapy in the contemporary management of metastatic prostate cancer

    BJU International

    Accepted manuscript online: 21 JUL 2014, Guru Sonpavde, Christopher G. Wang, Matthew D. Galsky, William K. Oh and Andrew J. Armstrong

    DOI: 10.1111/bju.12867

  17. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer

    The Prostate

    Volume 74, Issue 15, November 2014, Pages: 1544–1550, Arun A. Azad, Raya Leibowitz-Amit, Bernhard J. Eigl, Renee Lester, J. Connor Wells, R. Nevin Murray, Christian Kollmannsberger, Daniel Y.C. Heng, Anthony M. Joshua and Kim N. Chi

    Article first published online : 29 AUG 2014, DOI: 10.1002/pros.22872

  18. Pomegranate extract inhibits the bone metastatic growth of human prostate cancer cells and enhances the in vivo efficacy of docetaxel chemotherapy

    The Prostate

    Volume 74, Issue 5, May 2014, Pages: 497–508, Yanru Wang, Shumin Zhang, Shareen Iqbal, Zhengjia Chen, Xiaojing Wang, Yongqiang A. Wang, David Liu, Kevin Bai, Chad Ritenour, Omer Kucuk and Daqing Wu

    Article first published online : 23 DEC 2013, DOI: 10.1002/pros.22769

  19. Targeted therapy in prostate cancer

    Histopathology

    Volume 60, Issue 1, January 2012, Pages: 216–231, Niall M Corcoran and Martin E Gleave

    Article first published online : 23 DEC 2011, DOI: 10.1111/j.1365-2559.2011.04030.x

  20. You have free access to this content
    Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy

    BJU International

    Volume 110, Issue 11b, December 2012, Pages: E461–E468, Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, Lance Leopold, Matthew D. Galsky and Guru Sonpavde

    Article first published online : 23 APR 2012, DOI: 10.1111/j.1464-410X.2012.11148.x